1.
|
Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 Sponsor: Other Protocol IDs: P080204, IDRCB 2008-A01386-49, NCT00925444
|
|
2.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: Haema CBF SCLC UK/AS 01, NCT00168896
|
|
3.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: GLiang, NCT01498055
|
|
4.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000531141, CRUK-LUNGSTAR, EU-20649, ISRCTN56306957, EUDRACT-2005-005821-71, UCL-BRD/05/129, MREC-06-MRE10-28, CTA-20363-0215-001, CTAAC-C1312-A5335, CTAAC-C1312-A12462, NCT00433498
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000531709, CHNT-CONVERT, CHNT-CTAAC-CONVERT-C17052/A815, EU-20669, CHNT-CTAAC-CONVERT-C17052/A8152, NCT00433563
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: STAD-1, 2006-003995-36, NCT00526396
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-30610, CALGB 30610, RTOG 0538, NCT00632853
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ELCWP 01994, NCT00658580
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EudraCT number 2007-006033-14, NCT00717938
|
|
10.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DOLG7, NCT00812266
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: 19 to 80 Sponsor: Other Protocol IDs: CSCLC-0810, NCT00826644
|
|
12.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: ZhejiangCH06, NCT01158170
|
|
13.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA184-156, 2011-000850-48, NCT01450761
|
|
14.
|
Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: SCLC, NCT01487499
|
|
15.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IPM3002, NCT01555710
|
|
16.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: immatureDC- HMO-CTIL, NCT00278018
|
|
17.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: PX-171-007, NCT00531284
|
|
18.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PSHCI 08-005, NCT00702962
|
|
19.
|
Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 0359-08-HMO-CTIL, NCT00722228
|
|
20.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 79 Sponsor: Other Protocol IDs: F080929010, UAB 0818, NCT00856830
|
|
21.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C14007, 2008-006981-27, NCT01045421
|
|
22.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 100138, 10-C-0138, NCT01143545
|
|
23.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BRD 08/9-O, NCT01221675
|
|
24.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Immunogen 0007, NCT01237678
|
|
25.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2B3-101-CR-001, NCT01386580
|